In a nutshell These guidelines reviewed current recommendations on treating newly diagnosed classic Hodgkin lymphoma (cHL) in children and young adults, and cHL which has returned after previous treatment. Some background Hodgkin lymphoma is cancer of the lymph nodes, which are part of the immune system. It involves cancerous versions of B cells,...
Read More
In a nutshell This study evaluated the effectiveness and safety outcomes of pembrolizumab (Keytruda) plus GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) as second-line therapy for patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The data showed that the pembrolizumab plus GVD combination is safe and highly effective...
Read More
In a nutshell This study looked at the combination of brentuximab vedotin (BV; Adcetris) and ICE salvage chemotherapy with ifosfamide (Ifex), carboplatin (Paraplatin), and etoposide (Etopophos) for the treatment of relapsing or refractory Hodgkin lymphoma (HL). This study showed that BV-ICE was a good salvage treatment option for...
Read More
In a nutshell This study aimed to evaluate the long-term effectiveness and safety of high-dose chemotherapy (HDC) for the treatment of patients with unfavorable Hodgkin lymphoma (HL). The authors concluded that HDC increased the control of the disease in the long-term. Some background HDC with radiotherapy is a standard treatment of HL. 4 cycles of...
Read More
In a nutshell This study presents 5-year results for the targeted antibody therapy brentuximab vedotin (BV; Adcetris) for patients with advanced Hodgkin lymphoma (HL) who had not been previously treated. It found that BV with chemotherapy led to less recurrence of HL compared to chemotherapy alone. Some background The outcomes for patients with the...
Read More
In a nutshell This study reported the long-term effectiveness and safety outcomes of changing treatment intensity after a PET scan for patients with advanced-stage Hodgkin lymphoma (HL). The data showed that reducing treatment intensity after a negative PET scan and continuing standard-dose treatment after a positive PET scan was safe and effective over...
Read More
In a nutshell The authors compared the safety and effectiveness of pembrolizumab (Keytruda) and brentuximab vedotin (BV; Adcetris) for the treatment of patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The study found that pembrolizumab had better survival without cancer worsening compared to BV in these...
Read More
In a nutshell This study aimed to evaluate high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) for the treatment of patients with high-risk relapse (HRR) classical Hodgkin’s lymphoma (cHL). The authors concluded that the outcomes of patients with HRR cHL have improved over the last 15 years with...
Read More
In a nutshell This study investigated whether brentuximab vedotin (Adcedris; BC) + AVD (doxorubicin, vinblastine, and dacarbazine) chemotherapy combination resulted in a reduction or elimination of consolidative radiotherapy in early-stage unfavorable-risk Hodgkin lymphoma (HL). The data showed that the BV+AVD combination with and without...
Read More
In a nutshell This study evaluated the long-term outcomes of radiation, chemotherapy, or both for the treatment of patients with nodular lymphocyte-predominant Hodgkin’s lymphoma (NLPHL). The data showed that the overall survival was excellent regardless of treatment type. Some background NLPHL is an uncommon type of Hodgkin lymphoma...
Read More
In a nutshell This study investigated the safety and effectiveness of incorporating brentuximab vedotin (BV; Adcetris) as a substitution for vincristine in the OEPA (vincristine, etoposide, prednisone, doxorubicin) or COPD (cyclophosphamide, vincristine, prednisone, dacarbazine) chemotherapy regimen in children with high-risk classical...
Read More
In a nutshell The authors assessed the effectiveness of autologous stem cell transplantation (ASCT) after anti-PD-1 therapy for the treatment of patients with high-risk relapsed/refractory (r/r) Hodgkin lymphoma (HL). The study found that ASCT after anti-PD-1 therapy had very good outcomes in patients with r/r HL. Some background Standard...
Read More
